Bellerophon Therapeutics Inc (NASDAQ:BLPH) shares were up 5.8% during mid-day trading on Wednesday . The company traded as high as $0.58 and last traded at $0.55, approximately 196,234 shares were traded during trading. A decline of 24% from the average daily volume of 257,453 shares. The stock had previously closed at $0.52.

BLPH has been the subject of several analyst reports. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 target price for the company in a research report on Wednesday, May 15th. Maxim Group reaffirmed a “buy” rating and issued a $2.00 price target on shares of Bellerophon Therapeutics in a research note on Friday, August 9th. Finally, ValuEngine upgraded shares of Bellerophon Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 1st.

The company’s fifty day simple moving average is $0.62 and its two-hundred day simple moving average is $0.64. The company has a quick ratio of 2.64, a current ratio of 2.64 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $39.73 million, a price-to-earnings ratio of -1.62 and a beta of -0.02.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Equities research analysts expect that Bellerophon Therapeutics Inc will post -0.23 earnings per share for the current year.

Institutional investors have recently modified their holdings of the stock. LPL Financial LLC lifted its holdings in Bellerophon Therapeutics by 22.1% during the second quarter. LPL Financial LLC now owns 130,800 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 23,650 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Bellerophon Therapeutics by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 232,890 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 27,027 shares during the period. Arch Venture Corp acquired a new stake in shares of Bellerophon Therapeutics during the first quarter worth about $631,000. Vanguard Group Inc. raised its position in shares of Bellerophon Therapeutics by 15.9% during the second quarter. Vanguard Group Inc. now owns 1,152,175 shares of the biotechnology company’s stock worth $690,000 after purchasing an additional 158,000 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Bellerophon Therapeutics by 8.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,434,538 shares of the biotechnology company’s stock valued at $860,000 after purchasing an additional 116,862 shares in the last quarter. 53.36% of the stock is currently owned by institutional investors and hedge funds.

Bellerophon Therapeutics Company Profile (NASDAQ:BLPH)

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM.

Further Reading: Price to Earnings Ratio (PE) Basics

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.